sur Pentixapharm Holding AG (isin : DE000A40AEG0)
Pentixapharm Applauds CMS Reimbursement Enhancement for Radiopharmaceuticals
Pentixapharm Holding AG has expressed approval for the recent decision by the U.S. Centers for Medicare & Medicaid Services (CMS) to enhance reimbursement for specialized diagnostic radiopharmaceuticals. This policy change allows for separate payments beyond the transitional pass-through period, significantly affecting future reimbursement for Pentixapharm’s Ga68-PentixaFor. This diagnostic tool, intended for detecting primary aldosteronism (PA), is set to begin a Phase III clinical trial in the U.S. next year, with potential market authorization by 2028.
The CMS's previous policy covered high-cost diagnostics during a limited pass-through payment period, which then reverted to standard bundles. The new policy provides ongoing separate payments, influencing how hospitals adopt innovative technologies. As Medicare and Medicaid cover over 140 million Americans, this decision could lead private insurers to adopt similar reimbursement strategies, thus broadening access to advanced diagnostics.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pentixapharm Holding AG